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Abstract
To estimate causal effects of vaccine on post-infection outcomes, Hudgens and Halloran (2006) 
defined a post-infection causal vaccine efficacy estimand VEI based on the principal stratification 
framework. They also derived closed forms for the maximum likelihood estimators (MLEs) of the 
causal estimand under some assumptions. Extending their research, we propose a Bayesian 
approach to estimating the causal vaccine effects on binary post-infection outcomes. The 
identifiability of the causal vaccine effect VEI is discussed under different assumptions on 
selection bias. The performance of the proposed Bayesian method is compared with the maximum 
likelihood method through simulation studies and two case studies — a clinical trial of a rotavirus 
vaccine candidate and a field study of pertussis vaccination. For both case studies, the Bayesian 
approach provided similar inference as the frequentist analysis. However, simulation studies with 
small sample sizes suggest that the Bayesian approach provides smaller bias and shorter 
confidence interval length.
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1. Introduction
Estimating vaccine efficacy is crucial in evaluating the benefits of vaccines for public 
health. Evaluating the efficacy of prophylactic vaccines, i.e., whether the vaccine can 
prevent or ameliorate disease, is very important to reduce the burden of infectious disease 
[1]. In particular, a common objective of interest in vaccine studies is to evaluate and to 
compare post-infection outcomes, such as morbidity, mortality and secondary transmission 
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to others, in vaccinated individuals with those in unvaccinated individuals. However, 
treatment comparisons conditional on intermediate post-randomization outcomes using 
standard analytic methods would not necessarily allow a causal interpretation [2, 3]. 
Because the set of vaccinated individuals who become infected is not necessarily 
comparable to the set of unvaccinated individuals who become infected, comparisons of 
vaccine effects on outcomes conditional on infection could be biased [3, 4].
To address this problem, methods have been developed to assess causal treatment effects on 
post-infection outcomes. Kalbfleisch and Prentice [5] first discussed in the context of 
outcomes censored by death, about the importance of causal estimations in the subgroup of 
individuals whose outcomes hold meaning. Later, many pointed out that comparing 
outcomes only in the subpopulation in which individuals would become infected regardless 
of treatment assignment is a causal comparison [6-8]. Then in 2002, Frangakis and Rubin [9, 
10] proposed a general framework of principal stratification, which stratifies on the joint 
potential post-treatment variables, to estimate causal effects based on the potential outcomes 
framework [11, 12].
Principal strata are determined by the joint potential post-randomization outcomes under 
each treatment being compared. For example, principal effects are defined as the causal 
effects of treatment on a main outcome of interest (e.g., disease severity) within these 
principal strata [9]. Because these latent principal strata are not affected by treatment 
assignment, principal effects are causal effects that do not suffer from the complications of 
standard post-treatment adjusted estimands. More recently, this principal stratification 
framework has been adapted within the infectious disease context. For example, a few 
important methodological contributions have been developed to analyze principal effects in 
HIV prevention studies [13, 14]. However, generally we cannot directly observe the 
principal stratum to which a subject belongs because we usually cannot directly observe the 
potential post-randomization outcomes on different treatment assignments for the same 
subject [9].
Using the principal stratification framework, Hudgens and Halloran [15] defined a post-
infection causal vaccine efficacy estimand in the principal stratum of individuals who would 
be infected regardless of randomization to vaccine or placebo. They also investigated its 
estimation and identifiability under the standard assumptions: the stable unit treatment value 
assumption (SUTVA), independent treatment assignment, and monotonicity. Closed form 
maximum likelihood estimators (MLEs) were derived under some constraints. The methods 
were used to evaluate post-infection vaccine effects in a clinical trial of a rotavirus vaccine 
candidate and in a field study of a pertussis vaccination. Frequentist inference has also been 
commonly used in causal inference and other models in previous work [16, 17]. However, 
frequentist MLE inference can be biased, particularly when the sample size is small. 
Furthermore, maximum likelihood methods generally do not perform well when parameter 
estimates are on the boundary of the parameter space [18]. To deal with these issues, we 
propose a novel Bayesian approach via Markov chain Monte Carlo (MCMC) method to 
estimate the post-infection causal vaccine efficacy estimand. We compare the performance 
of the Bayesian method with a frequentist approach via maximum likelihood method with 
application to the two case studies mentioned above.
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The Bayesian approach has been increasingly used in recent years on clinical trials [19-24]. 
Under Frangakis and Rubin’s principal stratification and the Bayesian framework, Graham 
[20] defined a generalized population attributable fraction and applied it to an analysis of the 
low birth-weight cohort study. Odondi and McNamee [22] presented an optimal model 
selection predicting arm-specific compliance and produced causal risk ratio estimates for 
each principal stratum. Gao et al [23] discussed joint modeling of compliance and outcome 
for longitudinal studies when noncompliance was present. In general, a Bayesian approach 
provides a natural way to combine prior information with current data to make posterior 
inference that is exact conditional on the data without relying on asymptotic approximation 
[24]. It also provides better small-sample inferences and direct construction of equal-tail 
credible intervals on general functions of the estimated parameters [24, 25].
The remaining part of the paper is organized as follows. In Section 2, we review the 
assumptions, estimation and identifiability of the post-infection vaccine effect estimand 
from Hudgens and Halloran [15]. We also present their two motivating case studies, a field 
study of pertussis vaccination and a clinical trial of a rotavirus vaccine. In Section 3, we 
present a Bayesian approach to estimating the causal vaccine effects on binary post-infection 
outcomes through MCMC methods. In Section 4, we compare the results for the two 
motivating examples presented in Section 2. The performance of the proposed Bayesian 
approach is investigated through a series of simulations in Section 5. Finally we conclude 
with a brief discussion in Section 6. SAS code included in the Appendix describes the 
procedures to implement both the maximum likelihood method and the Bayesian approach.
2. Preliminaries
2.1 Assumptions and notation
Suppose that a group of n non-infected individuals receive treatment (vaccine) or control 
(placebo). Data on the intermediate outcome (infection status), as well as the outcome of 
interest (post-infection status), are collected. Assume the following:
A1. Stable Unit Treatment Value Assumption (SUTVA) [26-27]—Treatment 
assignment of one individual does not affect another individual’s outcomes (no 
interference), and there are not multiple versions of treatment.
Under SUTVA, let Si(Zi) denote the infection status (potential intermediate outcome) and 
Yi(Zi) denote the post-infection status (outcome of interest) of the ith individual given 
treatment assignment Zi, where Zi = p for placebo (control) and Zi = v for receiving vaccine 
(treatment). LetSi(Zi) = 1 if the ith individual is infected when received treatment Zi and 
Si(Zi) = 0 if uninfected. If Si(Zi) = 1 then let Yi(Zi) = 1 if the ith individual develops a severe 
post-infection outcome; and Yi(Zi) = 0 if no severe post-infection outcome observed. If Si(Zi) 
= 0 then we adopt the convention that Yi(Zi) is undefined and denoted by * [15, 28, 29]. 
Principal strata  are defined by classifying individuals according to the pair of potential 
infection outcomes, (Si(v),Si(p)). Basic principal stratification based on the potential 
infection outcomes with potential post-infection outcomes are listed in Table I.
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A2. Independent treatment assignment—The treatment assignment is independent of 
the potential outcomes, i.e., Z is independent of {Y(v),Y(p),S(v),S(p)}.
A3. Monotonicity—Si(v)≤Si(p) for all i ∈ {1,…,n}.
Under assumption A3, an individual who would become infected under vaccine would also 
become infected under placebo, so the “Harmed” principal stratum  is empty.
We suppose that all observed Zi,Si,Yi(Z)) are independent and identically distributed. Let 
nsy(z) be the number of each combination of infection outcome and post-infection outcome 
observed in the study population, where s = 0,1 is the observed infection outcome; y = 0,1,* 
is the observed post-infection outcome; and z = v,p. That is, 
, , 
, , 
, and 
where the summations are over i = 1,…,n. Let , and 
 denote the total number of individuals who receive placebo 
and vaccine, respectively.
2.2 Parameterization and estimation
Let the parameters θ =(θ00,θ01,θ11) be the probabilities associated with the principal strata, 
where  Let parameters φ = (φ00,φ01,φ10,φ11) 
be the probabilities associated with the joint potential post-infection outcomes in the 
doomed principal stratum , where 
 for k,m = 0,1. Let the parameters γ = 
(γ0,γ1) be the probabilities associated with the two possible potential post-infection 
outcomes under placebo in the protected principal stratum , where 
 for i = 0.1. Hudgens and Halloran [15] defined a post-
infection causal vaccine efficacy estimand VEI within the doomed principal stratum 
 as
(1)
where  and 
.
2.3 Identifiability
Hudgens and Halloran [15] showed that VEI is not identifiable under the standard 
assumptions A1-A3 (SUTVA, independence, and monotonicity). In particular, regarding the 
right hand side of equation (1), the numerator φ1. is identified by the observable random 
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variables but the denominator φ.1 is not identifiable. The MLE of φ1. is 
 which is the observed secondary attack rate in the vaccine 
arm. By considering different additional assumptions about the selective effect of the 
vaccine on susceptibility to infection, VEI becomes identifiable. The following are two 
situations we used in doing sensitivity analyses and simulation studies in Section 3 and 4.
2.3.1 No selection bias—The simplest assumption is that there is no selection bias; that 
is, the probability of the post-infection outcome conditional on infection under placebo is 
independent of infection status under vaccine, i.e., 
 for i = 0, 1. It is equivalent to 
say that the odds ratio of having the severe post-infection endpoint under placebo in the 
doomed versus protected principal strata is 1. Denote this odds ratio as exp(β), we have 
.
The no selection bias assumption implies φ.1 = γ1, thus the MLE of φ.1 is identifiable as 
. See equation (20) in Hudgens and Halloran [15]. Through 
the definition of VEI given in equation (1), it follows immediately that VEI becomes 
identifiable with the MLE .
2.3.2 Specified selection bias and/or fixed γ—When selection bias exists, eβ is not 
equal to 1. From the definitions of θ, φ and γ, one can identify that 
. Also, in terms of the definitions of φ.1, 
γ1 and eβ, one can easily derive that . Therefore, γ1 and π.1 can be 
solved for a specified eβ, and in turn, VEI becomes identifiable. A sensitivity analysis can 
then be performed over different value of eβ. The selection models we use in the Section 3 
are given by , 1 and 3. In Section 5, we do simulation studies on given values of eβ and 
γ1.
2.4 Two case studies
2.4.1 Rhesus rotavirus vaccine study—As the first motivating example, a 
randomized, double-blinded, placebo-controlled trial of a Rhesus rotavirus candidate vaccine 
[30] was conducted in children age 2-5 months from 1985 to 1987 in Finland. Children were 
randomized to vaccine or placebo, with 100 in each arm, i.e. n(v) = n(p) = 100. The vaccine 
efficacy was evaluated by comparing severity (mild vs. severe or moderately severe) 
between those vaccinated and unvaccinated children with confirmed rotavirus diarrhea. The 
observed data are shown in Table II.
2.4.2 Pertussis vaccine study—The second motivating example is an observational 
field study of pertussis vaccinatuon [31], which was conducted in Niakhar, Senegal from 
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January 1 to December 31, 1993, among children age 6 months through 8 years. The 
purpose of this study was to assess the beneficial effects of pertussis vaccination on 
preventing severe disease in breakthrough cases. The pertussis vaccine analysis included 
exactly one calendar year of follow-up, thus the person-years at risk can be used for n(v) and 
n(p), which were 3,845 and 1,020, respectively. Because there was no evidence of 
systematic differences between the vaccinated and unvaccinated groups, the independent 
treatment assignment assumption was reasonable. (See Section 3.4.2 in Hudgens and 
Halloran [15] for detailed discussion.) The observed data are shown in Table II.
3. Statistical Methods
3.1 The likelihood and posterior distribution
Since n(p) = n0*(p) + n11(p) and each of the three combinations is assumed to be observed at 
least once, the (n0*(p),n11(p)) follows a multinomial distribution with n = n(p) and parameter 
vector π(p) = (π0*(p),π10(p),π11(p)), where Σπsy(p) = 1 and 0 < πsy(Z) < 1 for (s,y) = (0,*),
(1,0),(1,1). Similarly, (n0*(v),n10(v),n11(v)) follows a multinomial distribution with 
parameter π(v = (π0*(v,π10(v),π11(v)). As all observed (Si,Yi) in placebo and vaccine groups 
are independent and identically distributed, these two multinomial distributions are 
independent conditional on the parameters π(p and π(v.
Using the same notations as in Hudgens and Halloran [15], the log-likelihood is proportional 
to  where 
, , and , and , . 
To simplify prior specifications, let , 
, , , , 
 and .  be prior joint 
distribution of α1,α2,αγ,απ and β, is proportional to 
Under most circumstances, inferences obtained by Bayesian and frequentist methods agree 
when weak prior distributions are specified. However, when suitable prior distributions can 
be constructed to incorporate known subject-matter information on model parameters, the 
Bayesian framework is particularly appealing [24, 32-33].
3.2 Posterior computation by using the Markov chain Monte Carlo method
Posterior computation was conducted using PROC MCMC procedure in SAS version 9.4 
(SAS Institute Inc. Cary NC). The SAS code is included in the Appendix. The burn-in 
consisted of 100,000 iterations, and 100,000 subsequent iterations were used for posterior 
summaries. Convergence of the MCMC chain was assessed using visual analysis via the 
SAS 9.4 PROC MCMC convergence diagnostic panel, including trace plots, sample 
autocorrelations, and kernel density plots, as well as the Gelman and Rubin convergence 
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statistics [34, 35]. The equal-tail 95% posterior credible intervals for VEI were directly 
available from the posterior samples.
3.3 Selection of prior distributions and sensitivity analyses
For the prior distributions of α1,α2,αγ and αφ, weak prior [36] N(0,2.52) was specified such 
that the 95% prior probability intervals for any of π0*(p),π10(p),π11(p) covered a sufficiently 
wide range of (0.001, 0.984), (0.002, 0.948) and (0.001, 0.943), respectively. Sensitivity 
analyses were performed for both Bayesian and frequentist methods over a range of different 
values of β, such that eβ, the odds ratio of having a severe post-infection endpoint under 
placebo in the doomed versus protected principal strata ranges from 1/3 to 3. When using 
the point-mass priors on β, the result from the Bayesian approach is comparable to that from 
the maximum likelihood method, but the former does not rely on large sample 
approximations. In addition, to incorporate the uncertainty related to the selection bias 
parameter eβ, we allow the prior of β to follow a normal distribution with unit variance in the 
Bayesian analysis.
3.4 Maximum likelihood method for comparison
By using a maximum likelihood based method, Hudgens and Halloran [15] derived closed 
forms for the MLE of the causal vaccine effect under some assumptions. To compare the 
performance of the Bayesian approach with that of the maximum likelihood method, the 
maximum likelihood estimation (MLE), 95% Wald type confidence intervals and profile 
likelihood confidence intervals [37] were also implemented with the SAS 9.4 PROC 
NLMIXED and PROC NLP procedures. The closed form MLE is derived under the 
assumption of nsy(Z) > 0 (see the Appendix in Hudgens and Halloran [15].) Thus, when 
using the maximum likelihood method, we check the condition of nsy(Z) > 0 for (s,y) = 
(0,*),(1,0),(1,1) and z = v,p first. The corresponding SAS code is included in the Appendix. 
The Wald type confidence intervals were obtained based on the normal approximation of 
log(1 – VEI
4. Results
The two case studies described in Section 2.4 were reanalyzed using Bayesian methods 
proposed in Section 3. Table III presents the VEI results under three values of eβ, for the 
pertussis vaccination and rotavirus vaccine case studies, respectively. Table III includes the 
maximum likelihood estimate, 95% Wald-type confidence interval, 95% profile likelihood 
confidence interval, posterior medians and 95% equal tailed credible intervals for VEI. The 
last two columns report VEI posterior results assuming that the prior distribution of VEI 
follows a normal distribution with variance 1. For the results of Bayesian analysis, columns 
at the left are posterior estimates when we specify point-mass priors on β, and the far right 
columns indicate results of fully Bayesian analysis (when we allow the prior of β to follow a 
normal distribution with unit variance).
We noticed that the last column of equal-tailed CI is wider than other CIs, probably due to 
the uncertainty introduced by the prior on β, which should be taken into consideration in the 
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data analysis. Other than that, no noticeable difference is observed in the VEI estimates or 
the average CI length between the maximum likelihood method and the Bayesian approach.
Figure 1 shows the MLE and Bayesian posterior median of VEI, with 95% Wald-type 
confidence interval, profile likelihood confidence interval, and Bayesian credible interval of 
VEI, over a range of eβ, where eβ is the odds ratio.
The results clearly demonstrate that the Bayesian posterior median is very close to the MLE 
of VEI. The 95% Wald-type confidence interval, profile likelihood confidence interval, and 
Bayesian credible interval are also similar, especially for the pertussis data, which has a 
relatively large sample size. However, for the rotavirus data, the posterior median is slightly 
lower than the maximum likelihood estimate. Moreover, the Bayesian credible interval tends 
to be narrower than the corresponding profile likelihood confidence interval. In addition, 
there is a notable difference between the Wald-type confidence interval and the other CIs for 
the rotavirus data. This is probably due to the poor performance of the asymptotic 
approximation for Wald type confidence intervals in studies with small to moderate sample 
sizes.
5. Simulation Study
5.1 Simulated data and analysis methods
We considered two sample sizes: 1) n(p) = 1,000, n(v) = 4,000; and 2) n(p) = n(v) = 100, 
which correspond to the pertussis vaccine study and rotavirus vaccine study, respectively. 
For each sample sizes, nine sets of simulations with different selection biases and vaccine 
effects were performed to evaluate the performance of the frequentist approach via the 
maximum likelihood methods and the Bayesian approach via MCMC methods. In particular, 
true values of VEI were set as 0.2, 0.5, and 0.8, respectively, while the odds ratio eβ values 
were set as 1/3, 1, and 3, thus nine combinations of true values were generated. True values 
of parameter π for the multinomial distributions were given as π(p) = (π0*(p),π10(p)π11(p)) 
= (0.8,0.1,0.1), which were close to the probabilities in the two case studies. By the 
relationship among parameters given in Section 3.1, π(v = (π0*(v),π10(v),π11(v)) were 
calculated under different values of VEI and eβ. Note that (i) γ1 was set as 0.4 when eβ = 3, 
and 0.6 when eβ = 1/3, to make sure all parameters are reasonable; (ii) when eβ = 1, θ01 = θ11 
was assumed, and γ1 was calculated as a fixed value π11(p)/(1 – π0*(p)) = 0.5. For each set 
of simulations, 1,000 replications were used.
5.2 Simulation results
Table IV summarizes the estimated bias, coverage of the 95% confidence/credible intervals, 
and average confidence/credible interval lengths of VEI from the frequentist approach and 
the Bayesian approach based on 1000 replications. As discussed in Section 3.4, if the 
condition nsy(Z)>0 for (s,y) = (0,*),(1,0),(1,1) is not met, some of the parameter estimates 
from MLE will be on the boundary of parameter spaces leading to some non-convergence 
computing issues through the frequentist approach. We only reported the number of 
simulations out of 1000 replicates that satisfy the condition for the maximum likelihood 
method. For the Bayesian approach, results are based on all 1000 replications, as Bayesian 
inference via MCMC algorithms permits full posterior inference (e.g., accurate credible 
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intervals) even in the absence of approximate normality [38], and does not have issues with 
parameter estimates on the boundary. To make the simulation results through the Bayesian 
approach directly comparable with those of the maximum likelihood method, we also 
reported the Bayesian simulation results for the subset in which the MLE is computable.
Similar findings on VEI were obtained by the proposed Bayesian method and the frequentist 
approach for large sample size. For small sample sizes, the Bayesian approach provided 
shorter CI length, and generally smaller bias. The Wald-type confidence interval gave the 
largest average CI length for small sample sizes, because of its poor performance of 
asymptotic approximation on small sample sizes. However, it may not be generalizable for 
the comparison based on the subset in which the MLE is directly computable, as it is a 
special subgroup from the 1000 replicates. For the Bayesian approach, we also reported 
biases based on all 1000 replicates. Meanwhile, the coverage probabilities are similar from 
those different methods.
6. Discussion
In this article, we proposed a Bayesian approach for estimating causal vaccine effects on 
binary post-infection outcomes, extending the MLE method by Hudgens and Halloran [15], 
with two application case studies. We further compared the performance of these two 
approaches through simulations. The use of the Bayesian approach provided similar 
inference with the frequentist analysis for both case studies. The Bayesian approach can give 
us smaller bias and shorter confidence interval length based on simulations for small 
datasets.
Recently, some concerns have been raised on the commonly used prior distributions for 
parameters [36, 39-41]. When prior information is not available, non-informative priors are 
often used to carry out Bayesian inference. However, in some situations, non-informative 
prior distributions may lead to high auto-correlation, where weakly informative priors based 
on the natural constraints of parameters are desired [36]. In our study, we specified weak 
prior distributions N(0,2.52) for α1,α2,αγ and αφ, so that the 95% prior probability intervals 
for any of π0*(p),π10(p),π11(p) would cover a sufficiently wide range of (0,1). For the 
selection bias parameter β, we first specified a point-mass prior on β (to make eβ = 1/3, 1 and 
3, respectively), such that the Bayesian approach is comparable to the frequentist sensitivity 
analysis. Then we allowed β to follow a normal distribution with a unit variance to 
incorporate the uncertainty related to eβ. Additionally, as pointed out by the reviewers, 
eliciting informative prior distributions on β would be worthwhile to further extend the 
research, especially for small datasets. Prior information is usually obtained from external 
data sources [42]. Several researchers have proposed methods to effectively incorporate 
expert opinions [43, 44, 46, 47] or published data via meta-analysis [45] as informative 
priors to improve posterior inference. For example, Liu et al proposed a Bayesian 
adjustment for misclassification of a binary exposure variable with informative prior from 
experts [46]. Scharfstein et al [47] discussed methods on eliciting informative priors for 
selection parameters from subject matter experts. Furthermore, as discussed in Section 2.3, 
VEI is not identifiable only under the standard assumptions A1-A3 (SUTVA, independence, 
and monotonicity). As Bayesian hierarchical models may include many latent and 
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unobservable variables, non-identifiability is an inevitable concern when using such models. 
Although non-identifiability might cause issues, Gustafson [44] showed that assigning a 
crude subjective prior to non-identifiable parameters (e.g. the β in our model) can perform 
better than fixing such parameters at best guess values.
Posterior computation can be accomplished using SAS PROC MCMC, as shown in the 
Appendix. The proposed Bayesian approach provides a useful alternative in estimating the 
post-infection causal vaccine effect. Although the Bayesian method has some advantages in 
this setting, as the frequentist method uses a different framework, and it is more familiar to 
most researchers, these two methods can be considered complementary. In most cases, 
inferences made by frequentist method and Bayesian approach agree when sample sizes are 
large and when weak prior distributions are specified [24, 25]. However, the Bayesian 
framework is particularly attractive when suitable prior distributions can be constructed to 
incorporate known constrains and subject-matter knowledge on model parameters [18], 
when the maximum likelihood estimates lie on the boundary of the parameters, or when the 
sample sizes are very small [48].
In addition to the possible extension on eliciting informative prior distributions on β, there 
are other areas of future research. For example, in this re-analysis of existed data, we only 
considered binary outcome. However, as discussed by Hudgens and Halloran [15] and 
pointed out by a referee, direct extensions to handle ordinal potential post-infection 
outcomes await for future research. Furthermore, additional research is needed on the 
consequences of relaxing key assumptions. The assumptions of A1-A3 can be violated [4, 
15], especially in observational studies on infectious diseases, which in turn will increase the 
complexity of defining, identifying and estimating causal effects. Some extensions have 
been developed and more are undergoing on estimating causal inference in the presence of 
interference [16, 49-51], noncompliance [52, 49], as well as incorporating baseline 
covariates [28, 53].
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SAS code for the frequentist and Bayesian approaches
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Figure 1. 
Comparison of VEI estimate* with 95% CI†using frequentist and Bayesian approach, as a 
function of the odds ratio eβ. a. Rotavirus vaccine study case; b. pertussis vaccine study case.
*
 MLE (bold dashed line), Bayesian posterior median (bold solid line).
†
 Wald-type confidence interval (fine dotted line), profile likelihood based confidence 
interval (fine dashed line), equal-tail credible interval (fine solid line).
The vertical dotted line corresponds to the assumption of no selection bias.
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Table I
Basic principal stratification SP0 based on the potential infection outcomes (Si(v),Si(p)) with potential post-
infection strata based on (Yi(v),Yi(p))
Principal stratum
SP0
Potential infection outcomes
(Si(v),Si(p))
Potential post-infection outcomes
(Yi(v),Yi(p))
Immune (0, 0) (*,*)
Harmed (1, 0) (0,*), (1,*)
Protected (0, 1) (*, 0), (*,1)
Doomed (1, 1) (0, 0), (1, 0), (0, 1), (1, 1)
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Table II
Observed data for the two case studies described in Section 2.4
Study n0*(p) n10(p) n11(p) n0*(v) n10(v) n11(v)
Rhesus rotavirus vaccine
(n(p)=100, (n(v)=100) 84 3 13 90 5 5
Pertussis vaccine
(n(p)=1020, (n(v)=3845) 814 77 129 3297 372 176
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Table III
Summary of (estimates* and 95% CI†) based on maximum likelihood and Bayesian approaches
Study eβ
Maximum likelihood method Bayesian approach
VEI Wald CI Profile VEI Equal-tail CI VEI 
‡ Equal-tail
CI‡
Rhesus
rotavirus
vaccine
1/3 0.340 (−0.334,0.674)
(−0.293,
0.724) 0.327
(−0.238,
0.702) 0.336
(−0.324,
0.709)
1 0.385 (−0.194,0.683)
(−0.081,
0.738) 0.376
(−0.091,
0.733) 0.375
(−0.118,
0.727)
3 0.430 (−0.085,0.701)
(0.026,
0.755) 0.407
(0.025,
0.750) 0.411
(−0.009,
0.745)
Pertussis
vaccine
1/3 0.424 (0.307,0.521)
(0.303,
0.519) 0.426
(0.303,
0.520) 0.439
(0.267,
0.563)
1 0.487 (0.397,0.563)
(0.397,
0.563) 0.486
(0.395,
0.563) 0.493
(0.337,
0.602)
3 0.543 (0.467,0.609)
(0.466,
0.609) 0.541
(0.462,
0.607) 0.542
(0.408,
0.634)
*
MLE of VEI for maximum likelihood method, posterior median of VEI for Bayesian approach.
†CI: Wald-type confidence interval based on normality assumption for the maximum likelihood method with standard errors derived from the 
observed information; profile likelihood confidence interval based on the value which maximizes the likelihood given the value of β; equal-tail 
credible interval for the Bayesian approach.
‡
The estimates when the prior of β follows a normal distribution with same mean and a unit variance.
Stat Med. Author manuscript; available in PMC 2017 January 15.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Zhou et al. Page 18
Ta
bl
e 
IV
Es
tim
at
ed
 b
ia
s*
,
 
em
pi
ric
al
 c
ov
er
ag
e 
pr
ob
ab
ili
ty
 o
f a
 9
5%
 co
nf
id
en
ce
/c
re
di
bl
e i
nt
er
va
l, 
an
d 
CI
†  
le
ng
th
 o
n 
VE
i b
as
ed
 o
n 
10
00
 re
pl
ic
at
io
ns
VE
I
eβ
M
ax
im
um
 L
ik
el
ih
oo
d 
M
et
ho
d
Ba
ye
sia
n 
A
pp
ro
ac
h
n
‡
Bi
as
W
al
d 
C
I
Pr
of
ile
 C
I
Bi
as
Eq
ua
l-t
ai
l C
I (
n=
n‡
)
Bi
as
Eq
ua
l-t
ai
l C
I (
n=
10
00
)
C
ov
er
ag
e
pr
ob
ab
ili
ty
C
I
le
ng
th
C
ov
er
ag
e
pr
ob
ab
ili
ty
C
I l
en
gt
h
C
ov
er
ag
e
pr
ob
ab
ili
ty
C
I
le
ng
th
C
ov
er
ag
e
pr
ob
ab
ili
ty
C
I
le
ng
th
Fo
r 
sm
al
l s
am
pl
e 
siz
e 
(n(
p) 
= 1
00
, n
(v)
 = 
10
0)
1/
3
87
2
−
0.
22
3
0.
95
0
3.
71
0
0.
95
6
3.
16
7
−
0.
17
3
0.
95
9
2.
81
2
−
0.
10
0
0.
93
3
2.
70
6
0.
2
1
97
5
−
0.
07
4
0.
95
8
1.
87
3
0.
94
2
1.
78
3
−
0.
07
5
0.
94
2
1.
71
5
−
0.
06
6
0.
92
7
1.
70
2
3
95
0
−
0.
02
5
0.
97
5
1.
52
2
0.
97
6
1.
45
4
−
0.
04
6
0.
97
7
1.
42
3
−
0.
04
9
0.
95
9
1.
41
7
1/
3
71
8
−
0.
29
7
0.
93
3
3.
50
8
0.
96
4
2.
79
3
−
0.
27
1
0.
96
4
2.
48
8
−
0.
11
2
0.
95
9
2.
20
0
0.
5
1
92
1
−
0.
09
3
0.
94
2
1.
71
8
0.
95
5
1.
47
7
−
0.
10
4
0.
95
7
1.
42
4
−
0.
06
6
0.
93
5
1.
36
9
3
91
5
−
0.
07
7
0.
94
3
1.
49
7
0.
96
9
1.
27
9
−
0.
10
1
0.
96
6
1.
25
6
−
0.
07
2
0.
94
2
1.
21
8
1/
3
42
7
−
0.
39
1
0.
86
9
3.
38
1
0.
94
1
2.
43
2
−
0.
39
1
0.
91
6
1.
18
8
−
0.
15
2
0.
96
2
1.
68
0
0.
8
1
62
9
−
0.
14
7
0.
91
7
1.
56
5
0.
95
7
1.
57
8
−
0.
16
9
0.
94
3
1.
12
8
−
0.
06
4
0.
96
4
0.
94
0
3
62
8
−
0.
14
3
0.
91
2
1.
41
9
0.
96
0
1.
03
0
−
0.
17
0
0.
94
9
1.
02
3
−
0.
06
7
0.
96
6
0.
86
5
Fo
r 
la
rg
e 
sa
m
pl
e 
siz
e 
(n(
p) 
= 1
,00
0, 
n
(v)
 = 
4,0
00
)
1/
3
10
00
−
0.
00
4
0.
94
8
0.
45
2
0.
94
8
0.
45
3
−
0.
00
2
0.
94
8
0.
45
2
0.
2
1
10
00
0.
00
1
0.
95
2
0.
29
7
0.
95
0
0.
29
9
0.
00
05
0.
94
9
0.
29
8
3
10
00
−
0.
00
3
0.
95
0
0.
23
8
0.
94
5
0.
24
1
−
0.
00
4
0.
94
6
0.
24
1
1/
3
10
00
−
0.
00
2
0.
95
1
0.
33
3
0.
95
1
0.
33
2
−
0.
00
2
0.
94
8
0.
33
1
0.
5
1
10
00
0.
00
1
0.
95
2
0.
22
2
0.
95
2
0.
22
2
0.
00
1
0.
95
2
0.
22
2
Sa
m
e 
as
 (n
=n
‡ )
3
10
00
−
0.
00
1
0.
94
9
0.
19
2
0.
94
1
0.
19
3
−
0.
00
3
0.
94
2
0.
19
3
1/
3
10
00
−
0.
00
1
0.
95
1
0.
19
6
0.
94
7
0.
19
2
−
0.
00
2
0.
94
8
0.
19
1
0.
8
1
10
00
0.
00
1
0.
95
5
0.
13
2
0.
95
1
0.
13
1
0.
00
1
0.
94
8
0.
13
1
3
10
00
−
0.
00
1
0.
94
1
0.
12
5
0.
93
8
0.
12
3
−
0.
00
1
0.
93
8
0.
12
3
*
B
ia
s: 
M
LE
 o
f V
E I
 
m
in
us
 tr
ue
 v
al
ue
 o
f V
E I
 
fo
r m
ax
im
um
 li
ke
lih
oo
d 
m
et
ho
d;
 p
os
te
rio
r m
ed
ia
n 
of
 V
E I
 
m
in
us
 tr
ue
 v
al
ue
 o
f V
E I
 
fo
r B
ay
es
ia
n 
ap
pr
oa
ch
.
Stat Med. Author manuscript; available in PMC 2017 January 15.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Zhou et al. Page 19
† C
I: 
W
al
d-
ty
pe
 c
on
fid
en
ce
 in
te
rv
al
 b
as
ed
 o
n 
no
rm
al
ity
 a
ss
um
pt
io
n 
of
 lo
g(1
 – 
VE
I) 
for
 th
e m
ax
im
um
 lik
eli
ho
od
 m
eth
od
 de
riv
ed
 fr
om
 th
e o
bs
erv
ed
 in
for
ma
tio
n; 
pro
fil
e l
ike
lih
oo
d c
on
fid
en
ce
 in
ter
va
l b
ase
d 
o
n
 th
e 
VE
I v
al
ue
 w
hi
ch
 m
ax
im
iz
es
 th
e 
lik
el
ih
oo
d 
gi
ve
n 
th
e 
va
lu
e 
of
 β;
 e
qu
al
-ta
il 
cr
ed
ib
le
 in
te
rv
al
 fo
r t
he
 B
ay
es
ia
n 
ap
pr
oa
ch
.
‡ n
: 
th
e 
nu
m
be
r o
f r
ep
lic
at
io
ns
 th
at
 sa
tis
fy
 th
e 
co
nd
iti
on
 n
sy
(z)
 > 
0 f
or 
(s,
 y
) =
 (0
,*)
,(1
, 0
), (
1, 
1).
Stat Med. Author manuscript; available in PMC 2017 January 15.
